Unlocking the Healing Power of Cellular Reprogramming: Tenaya Therapeutics’ Preclinical Data Published in Circulation
Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Novel AAV-Based Approach Regenerated Myocardial Cells and Demonstrated Durable Benefit to Heart Function in Rodent Model of Chronic Cardiac Ischemic Injury SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop…